Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several core facts align with the label (brand, indication concept for SLE and lupus nephritis, IV/SC routes, BLyS mechanism, and key serious risks like serious infections/hypersensitivity/PML). However, multiple details are inaccurate or unsupported by the provided label excerpts, most notably dosing frequency for SC injections (once weekly) across indications, and the inclusion of diarrhea/rash/headache as common side effects without support in the provided safety section. Also, the label excerpts do not mention manufacturer.
Category Scores
Accurate Statements
Belimumab is marketed under the brand name Benlysta.
Drug is BENLYSTA; active ingredient belimumab (provided label excerpts header/active ingredient context).
Benlysta is a BLyS-specific inhibitor.
Section 12.1: “BENLYSTA is a BLyS-specific inhibitor…”
BLyS is a protein that promotes the survival of B-lymphocytes.
Section 12.1: “…soluble BLyS (B-cell survival factor)…”
Benlysta can be administered as an intravenous (IV) infusion.
Section 2.1: “may be administered intravenously or subcutaneously”; Section 2.2 describes IV infusion.
Benlysta can be administered as a subcutaneous injection.
Section 2.1: “may be administered intravenously or subcutaneously”; Section 2.3 describes SC administration.
More serious side effects of Benlysta can include infections.
Section 5.1: “Serious and sometimes fatal infections…”; Section 6.1: “Serious infections…”
More serious side effects of Benlysta can include hypersensitivity reactions.
Section 5.2: “Acute hypersensitivity reactions, including anaphylaxis…”; Section 6.1: “Hypersensitivity Reactions, including Anaphylaxis…”
A rare but serious side effect of Benlysta is progressive multifocal leukoencephalopathy (PML), a brain infection.
Section 5.1: “Progressive Multifocal Leukoencephalopathy (PML)… neurological deficits, including fatal cases…”
Unsupported Statements
Common side effects of Benlysta include nausea.
The provided adverse reactions excerpt (Section 6.1) lists serious adverse reactions categories and specific trial rates for hypersensitivity/anaphylaxis/serious infections/depression; it does not state nausea as a common side effect.
Common side effects of Benlysta include diarrhea.
No diarrhea listed as a common side effect in the provided label excerpts.
Common side effects of Benlysta include fever.
No fever listed as a common side effect in the provided label excerpts.
Common side effects of Benlysta include rash.
No rash listed as a common side effect in the provided label excerpts.
Common side effects of Benlysta include headache.
No headache listed as a common side effect in the provided label excerpts.
Benlysta is manufactured by GlaxoSmithKline (GSK).
The provided prescribing information excerpts do not state the manufacturer.
Contradictions
Low
AI Statement
The subcutaneous injection of Benlysta is typically given once a week.
Label Reference
Section 2.3 subcutaneous dosage: for active SLE, patients 15 kg to <40 kg receive 200 mg once every 2 weeks (not once weekly); for active lupus nephritis, dosing also differs by weight during some phases.
Important Omissions
Benlysta labeling (Section 1) specifies treatment for patients 5 years of age and older, receiving standard therapy; the claims provided repeatedly specify “adult patients” without mentioning the minimum age threshold (5+).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most safety categories referenced (serious infections, hypersensitivity including anaphylaxis, and PML) are supported by the excerpts. However, incorrect/unsupported details (SC dosing frequency oversimplified; several “common side effects” listed without support) could mislead expectations about adverse effects or dosing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Subcutaneous dosing frequency statement is oversimplified/incorrect for some weight groups; several purported common side effects and the manufacturer are not supported by the provided label excerpts.
Suggested Improvement
Replace the SC frequency claim with the weight- and indication-specific regimen from Section 2.3; remove or revise the unsupported “common side effects” (nausea/diarrhea/fever/rash/headache) unless supported by the full label; avoid stating manufacturer unless present in the label; ensure age-eligibility language (≥5 years) is accurate if discussing labeling scope.